Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
Completed
- Conditions
- Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Registration Number
- NCT00090090
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Brief Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 114
Inclusion Criteria
- Relapsed or Refractory mantle cell lymphoma and/or CLL/SLL except Burkitt's, Burkitt's like or HIV-associated lymphoma
- at least one prior cytotoxic chemotherapy regimens
- measurable disease
- adequate bone marrow, liver and kidney function
- ECOG PS 0-2
Exclusion Criteria
- prior treatment with elsamitrucin
- prior chemo, antibody or radiotherapy for NHL within 28 days prior to start to treatment
- HIV positive or known AIDS syndrome
- uncontrolled medical disease or psychiatric condition/s
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Alta Bates Cancer Center
🇺🇸Berkeley, California, United States
Cancer and Blood Institute Medical Group
🇺🇸Rancho Mirage, California, United States
Tower Hematology Oncology Medical Group
🇺🇸Los Angeles, California, United States
Providence Saint Joseph Medical Center
🇺🇸Burbank, California, United States
North Shores University Hospital
🇺🇸Manhasset, New York, United States
North Valley Hematology Oncology Medical Group
🇺🇸Mission Hills, California, United States
USC Norris Cancer Center
🇺🇸Los Angeles, California, United States